---

Do GLP-1 medications make you dehydrate faster in the heat?

This question comes up in my office every summer, and it deserves a careful answer rather than a scary one. Living in Mesa, we already ask more of our bodies from May through September than most of the country does all year. So when a medication changes how much you drink, that matters here in a way it might not somewhere else.

In two decades of practicing medicine I have learned to separate what is proven from what is reasonable to expect. Let me do that here, because on this topic the two are not the same.

The honest starting point

No study has tested GLP-1 medications, body temperature regulation, and heat illness in a hot climate. None. Anyone who tells you the risk is proven is going beyond the evidence, and anyone who tells you there is nothing to think about is ignoring the mechanism. What we have is solid evidence about what these drugs do to thirst and fluid balance, and a reasonable inference about what that means in a Phoenix August.

I am telling you that up front because the inference is worth acting on even without the trial. The steps involved cost nothing and carry no downside.

These medications turn down thirst

This is the part most patients have never been told. GLP-1 receptor agonists reduce not just appetite but thirst, through mechanisms in the brain that work independently of the effect on eating.

• In a randomized crossover trial in people who drink excessively, dulaglutide cut voluntary fluid intake by about 490 mL over eight hours — a 17 percent reduction — and lowered the sense of thirst triggered by seeing a drink.
• In healthy volunteers with normal fluid status, the effect was much smaller and not statistically significant, though urine output over 24 hours did fall. That suggests the thirst suppression shows up most in people who were drinking a lot to begin with.
• Animal work confirms the effect is central and persists with the long-acting drugs.

Read that middle point carefully, because it cuts both ways. In ordinary conditions, the effect on a healthy person is modest. The concern is not ordinary conditions.

And they change how your kidneys handle water

Two things happen at once. These drugs suppress the vasopressin system — the hormone signal that tells your kidneys to hold onto water. Dulaglutide lowered a marker of that system by about 12 percent in people with normal fluid status, and liraglutide lowered the hormone itself in healthy humans. At the same time, GLP-1 medications increase the excretion of sodium and water.

So you have less signal to drink, and slightly more water going out. In a normally hydrated person sitting in air conditioning, the body compensates and blood sodium stays normal. That compensation is what gets tested when you add heat.

What the safety reports actually show

A review of the FDA’s adverse event reporting database found that dehydration was the most frequent metabolic and nutritional adverse event contributing to serious outcomes across liraglutide, dulaglutide, semaglutide, and tirzepatide — and it tended to appear early rather than after years of use.

Now the balancing facts, because this is where people either panic or dismiss it, and neither is right. Most of that dehydration, and the kidney injury that sometimes follows, is attributed to gastrointestinal losses — nausea, vomiting, diarrhea — rather than to blunted thirst itself. Drug labels carry case reports of kidney injury from volume depletion. But large trials and pooled analyses have not shown an overall increase in kidney injury risk. There are rare reports of tirzepatide-associated metabolic acidosis, and those occurred in people who were dehydrated and not eating or drinking.

Put plainly: for most people, most of the time, these medications do not cause dangerous dehydration. The risk concentrates in specific windows, and those windows are predictable.

Why Arizona changes the math

Stack the factors and you can see why I bring this up with every patient who starts a GLP-1 here. Blunted thirst. Increased water and sodium excretion. Lower total fluid intake because you are eating and drinking less overall. Then add what a 110-degree day does — heavy sweat losses you barely notice because it evaporates instantly, plus the water you lose just breathing dry air. Add a stomach bug or a rough week of dose escalation on top and you have four things pulling the same direction at once.

None of those factors alone is likely to hurt you. Converging, in July, on a hike or a job site, they can.

What to actually do about it

• Stop using thirst as your gauge. This is the single most important change. Your thirst signal is being medicated. Put fluids on a schedule instead — a set amount at set times through the day, whether or not you want it.
• Drink before heat, not after. Front-load before yard work, a hike, a round of golf, or a shift outdoors. Catching up afterward is harder than staying ahead.
• Be extra careful during dose increases. That is when the stomach side effects and the dehydration reports cluster. If your dose is going up in July, that week deserves more attention, not less.
• Have a plan for sick days. Vomiting or diarrhea while on a GLP-1 in Arizona summer is the highest-risk combination on this page. That is a call to the office, not a wait-and-see.
• Watch your urine. Output that drops off, or color that stays dark, is your most reliable early warning when thirst is not.
• Tell me what else you take. Blood pressure medications, diuretics, and anti-inflammatories change this equation. That is a conversation, not a guess.

I am deliberately not putting a number of ounces on this page. The right amount depends on your kidney function, your heart, your other medications, and what your day looks like — and for some patients, drinking too much plain water carries its own risk. We set that target together, with your labs in front of us.

Call us the same day if

• You cannot keep fluids down, or you have had vomiting or diarrhea for more than a day.
• You feel lightheaded standing up, or your heart is racing at rest.
• You are urinating much less than usual.
• You have muscle cramps, a headache that will not clear, or unusual weakness after heat exposure.

Confusion, fainting, or a seizure is 911, not a phone call to us.

Measure, don’t guess

None of this is a reason to avoid a GLP-1. These medications are doing real good for my patients, and the benefits go well past the scale. It is a reason to take one specific side effect seriously in one specific climate. Kidney function, electrolytes, and blood pressure are simple to check, and checking them is how we keep a medication that is helping you from causing a problem it does not need to cause. Related reading: heat stroke vs heat exhaustion, GLP-1 side effects, GLP-1 benefits beyond weight loss, and can you reverse diabetes.

Text us at 480-485-2197 to schedule, or call. Quick response, real scheduling, no phone tree.

To Health and Wellness,
Dr. Tallman

---

References

This page covers general health information and is not a substitute for individual medical advice. Never start, stop, or change a prescription medication on your own. If you are having symptoms, call your physician.

• The Journal of Clinical Investigation, 2021 — randomized controlled trial of dulaglutide in primary polydipsia.
• Endocrine, 2020 — effects of GLP-1 receptor agonists on fluid intake in healthy volunteers.
• American Journal of Physiology, 2011 — GLP-1 receptor agonists suppress water intake independent of effects on food intake.
• European Journal of Endocrinology, 2026 — effects of GLP-1 receptor agonists on copeptin in euvolemic participants.
• Science Advances, 2026 — liraglutide effects on the brain-kidney axis.
• Frontiers in Pharmacology, 2024 — pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events.
• The American Journal of Emergency Medicine, 2024 — GLP-1 agonists: a review for emergency clinicians.
• Drugs, 2025 — safety and tolerability of GLP-1 receptor agonists: state-of-the-art narrative review.
• EClinicalMedicine, 2026 — balancing the benefits and risks of GLP-1 receptor agonists: a clinical guide for shared decision-making.
• JAMA Cardiology, 2020 — GLP-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease.